Skip to content
    Clinical Trials

    Remote Symptom Monitoring and Acute Care Utilization in Advanced Cancer Trials

    Stover et alCancers

    Remote Symptom Monitoring and Acute Care Utilization in Advanced Cancer Trials
    In a secondary analysis of a randomized clinical trial involving patients with advanced cancer receiving phase I therapies, incorporating remote symptom monitoring (RSM) into specialist palliative care (SPC) did not reduce emergency department (ED) visits or hospitalizations over 6 months.
    The study evaluated 100 patients (mean age 56 years, 63% female, median survival 221 days [95% CI 171, 271]), with 43 patients randomized to SPC alone and 57 randomized to SPC plus RSM. Over 6 months of follow-up, at least one ED visit occurred in 51% (22/43) of patients receiving SPC alone compared to 53% (30/57) receiving SPC+RSM (p = 0.58). Hospitalization rates were also similar between study arms, occurring in 42% (18/43) of SPC patients and 37% (21/57) of SPC+RSM patients (p = 0.56).
    Pain and respiratory symptoms were the most common presenting complaints, accounting for 27% and 22% of ED visits and 29% and 22% of hospital admissions, respectively. The primary underlying etiologies for acute care encounters were disease progression (49% of ED visits, 58% of hospitalizations) and acute complications (26% of ED visits, 28% of hospitalizations). Evaluation by two independent reviewers determined that only 5% (4/84) of ED visits and 0% (0/57) of hospitalizations were potentially avoidable, highlighting that acute care events in this cohort were largely unavoidable and underscoring the need for novel strategies to support patients undergoing phase I oncology trials.

    Key Takeaways

    • Adding remote symptom monitoring to specialist palliative care did not reduce 6-month rates of emergency department visits (53% vs 51%, p = 0.58) or hospitalizations (37% vs 42%, p = 0.56) in patients with advanced cancer receiving phase I therapies.
    • Acute care encounters were driven primarily by disease progression (49% of ED visits, 58% of hospitalizations) and acute complications (26% of ED visits, 28% of hospitalizations), with only 5% (4/84) of ED visits and 0% (0/57) of hospitalizations deemed avoidable.